Skip to main content
Premium Trial:

Request an Annual Quote

Startup Blackfield Supporting AstraZeneca with Genomics, Computational Biology Services

NEW YORK (GenomeWeb News) – German startup biotech firm Blackfield today announced a collaboration with AstraZeneca in support of one of the biopharmaceutical firm's oncology drug development programs.

Blackfield will apply its genomics technologies and computational biology capabilities to validate preclinical models in support of AstraZeneca's program it said. Further details of AstraZeneca's program were not revealed.

Blackfield said that today's deal is its fourth since starting up a year ago. It also has service agreements with Janssen Pharmaceuticals, a division of Johnson & Johnson; Merck KGaA; and Boehringer Ingelheim.

Financial and other terms of the deal with AstraZeneca were not disclosed.

Based in Cologne, Blackfield generates datasets of genomic changes in various types of cancer, then applies computation biology to support the development of methods to molecularly diagnose and treat cancer.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.